Investing.com - Financial Markets Worldwide

Chemomab prepares for annual shareholder meeting

Published 27/05/2025, 21:16
Chemomab prepares for annual shareholder meeting
CMMB
-0.01%

Chemomab Therapeutics Ltd., a company specializing in pharmaceutical preparations, announced today, May 27, 2025, the upcoming schedule for its annual general meeting of shareholders. The meeting is set to take place on July 1, 2025, and will include discussions on proposals that are crucial for the company’s future operations and governance.

In an SEC Form 6-K filing, Chemomab furnished documents related to the annual general meeting, including a Notice and Proxy Statement and a Proxy Card. The Notice and Proxy Statement details the proposals to be deliberated upon during the meeting, outlines the voting procedures for shareholders, and provides other relevant information about the event. The Proxy Card is designed for holders of American Depository Shares, allowing them to vote without being present at the meeting in person.

This filing is also incorporated by reference into the company’s Registration Statements on Form F-3 and Form S-8, which are part of the regulatory requirements for public companies.

Chemomab Therapeutics, previously known as Anchiano Therapeutics Ltd (NASDAQ:CMMB). and BioCancell Ltd., has undergone name changes in the past, reflecting its evolving business focus. The company is incorporated in Israel and operates out of Tel Aviv.

The announcement and related materials were signed by Sigal Fattal, the company’s Chief Financial Officer, indicating the formal and legal declaration of the company’s intent to hold the shareholder meeting as per the SEC’s regulations.

This news comes as part of the company’s regular corporate governance and compliance with SEC regulations for foreign private issuers. The annual general meeting is an essential part of the company’s engagement with its shareholders, providing a platform for decision-making and updates on the company’s performance and strategy.

The information for this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.